CVRx (NASDAQ:CVRX) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

CVRx (NASDAQ:CVRX - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.01, FiscalAI reports. The company had revenue of $14.69 million for the quarter, compared to the consensus estimate of $14.16 million. CVRx had a negative net margin of 95.61% and a negative return on equity of 79.31%. CVRx updated its Q4 2025 guidance to EPS and its FY 2025 guidance to EPS.CVRx Stock PerformanceCVRX stock traded down $0.20 during midday trading on Wednesday, hitting $9.79. 227,522 shares of the stock traded hands, compared to its average volume of 290,381. CVRx has a 1-year low of $4.30 and a 1-year high of $18.55. The company has a debt-to-equity ratio of 0.85, a current ratio of 11.99 and a quick ratio of 10.78. The firm has a market cap of $256.03 million, a P/E ratio of -4.66 and a beta of 1.28. The stock's fifty day simple moving average is $8.61 and its 200-day simple moving average is $7.49. Analysts Set New Price TargetsA number of research firms have recently weighed in on CVRX. Weiss Ratings reiterated a "sell (e+)" rating on shares of CVRx in a research note on Thursday, October 30th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $11.00 price target on shares of CVRx in a research report on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $14.00.Read Our Latest Research Report on CVRxInstitutional Investors Weigh In On CVRxA number of institutional investors have recently modified their holdings of CVRX. XTX Topco Ltd acquired a new stake in CVRx in the second quarter valued at approximately $155,000. Cresset Asset Management LLC grew its holdings in CVRx by 3.5% in the second quarter. Cresset Asset Management LLC now owns 53,542 shares of the company's stock valued at $315,000 after purchasing an additional 1,823 shares during the period. Bank of America Corp DE grew its stake in CVRx by 7.6% in the 2nd quarter. Bank of America Corp DE now owns 89,049 shares of the company's stock valued at $524,000 after acquiring an additional 6,312 shares during the period. Marshall Wace LLP grew its stake in CVRx by 238.1% in the 2nd quarter. Marshall Wace LLP now owns 350,080 shares of the company's stock valued at $2,058,000 after acquiring an additional 246,548 shares during the period. Finally, Geode Capital Management LLC grew its stake in CVRx by 6.4% in the 2nd quarter. Geode Capital Management LLC now owns 382,437 shares of the company's stock valued at $2,249,000 after acquiring an additional 23,079 shares during the period. 75.27% of the stock is currently owned by institutional investors and hedge funds. About CVRx (Get Free Report)CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.Featured StoriesFive stocks we like better than CVRxThe Significance of a Trillion-Dollar Market Cap Goes Beyond a Number3 Cash-Rich Stocks With High Growth Potential Right NowDo ETFs Pay Dividends? What You Need to KnowWhy Vertical Aerospace Stock Could Double After This Flight TestThe Significance of Brokerage Rankings in Stock SelectionAmazon: Breakout Confirmed—Here’s Where It Could Go NextThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in CVRx Right Now?Before you consider CVRx, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVRx wasn't on the list.While CVRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here